> 암의병기 > 그외병기 > 흑색종 병기
AJCC Tumor depth
| Tumor depth (mm) |
|---|
| ≤1.0 mm |
| 1.1 – 2 mm |
| 2.1 – 4 mm |
| ＞ 4 mm |
Staging System for Cutaneous Melanoma of the AJCC(2010년 기준)
| Primary tumor (T) | ||
|---|---|---|
| Tx | Primary tumor cannot be assessed | |
| T0 | No evidence of primary tumor | |
| Tis | Melanoma in situ | |
| T | size ≤ 1.0 ㎜ | |
| T1a | without ulceration and mitoses ＜1/㎟ | |
| T1b | with ulceration or mitoses ≥1/㎟ | |
| T2 | 1.0 mm ＜ size ≤ 2.0 ㎜ | |
| T2a | without ulceration | |
| T2b | with ulceration | |
| T3 | 2.0 mm ＜ size ≤ 4.0 ㎜ | |
| T3a | without ulceration | |
| T3b | with ulceration | |
| T4 | size ＞4.0 ㎜ | |
| T4a | without ulceration | |
| T4b | with ulceration | |
| Regional lynph node (N) | ||
|---|---|---|
| Nx | Patients in whom the regional nodes cannot be assessed | |
| N0 | No regional metastases detected | |
| N1 | 1 Lymph node | |
| N1a | micrometastases* | |
| N1b | macrometastases† | |
| N2 | 2-3 Lymph node | |
| N2a | micrometastases* | |
| N2b | macrometastases† | |
| N2c | in-transit met(s)/satellite(s) without metastatic lymph nodes | |
| N3 | ≧4 metastatic lymph nodes, or matted lymph nodes, or in-transit met(s)/satellite(s) with metastatic lymph node(s) | |
| Distant metastasis (M) | ||
|---|---|---|
| M0 | No detectable evidence of distant metastasis | |
| M1 | ≧ 1 distant metastasis | |
| M1a | Metastasis to skin, subcutaneous, or distant lymph node, normal serum LDH | |
| M1b | Lung metastasis, normal LDH | |
| M1c | Metastasis to other visceral metastases with a normal LDH, or any distant metastases and an elevated LDH | |
* Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).
†Macrometastases are defined as clinically detectable lymph node metastases confirmed by therapeutic lymphadenectomy or when any lymph node metastasis exhibits gross extracapsular extension
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.
| Stage | Clinical staging* |
|---|---|
| 0 | Melanoma in situ, Clark level I (TisN0M0) |
| IA | T1aN0M0 |
| IB | T1aN0M0 or T2aN0M0 |
| IIA | T2bN0M0 or T3aN0M0 |
| IIB | T3bN0M0 or T4aN0M0 |
| IIC | T4bN0M0 |
| III | any T, N1-3, M0 |
| IV | Distant metastasis (any T, any N, M1) |
| Stage | Pathologic staging† |
|---|---|
| 0 | Melanoma in situ, Clark level I (TisN0M0) |
| IA | T1aN0M0 |
| IB | T1aN0M0 or T2aN0M0 |
| IIA | T2bN0M0 or T3aN0M0 |
| IIB | T3bN0M0 or T4aN0M0 |
| IIC | T4bN0M0 |
| IIIA | (T1-4a, N1a, M0) or (T1-4a, N2a, M0) |
| IIIB | (T1-4b, N1a, M0) or (T1-4b, N2a, M0) or (T1-4a, N1b, M0) or (T1-4a, N2b, M0) or (T1-4a, N2c, M0) |
| IIIC | (T1-4b, N1b, M0) or (T1-4b, N2b, M0) or (T1-4b, N2c, M0) or (T1-4b, N3, M0) |
| IV | Distant metastasis (any T, any N, M1) |
* Clinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for metastases. By convention, it should be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.
† Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy. Pathologic Stage 0 or Stage IA patients are the exception; they do not require pathologic evaluation of their lymph nodes.
Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.
